StockNews.com Lowers Teva Pharmaceutical Industries (NYSE:TEVA) to Buy

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Monday.

A number of other analysts have also issued reports on TEVA. The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a research report on Monday, February 5th. Jefferies Financial Group raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and upped their target price for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Piper Sandler reiterated an "overweight" rating and set a $20.00 target price (up from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, May 13th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price target for the company in a research note on Friday, March 8th. Finally, Barclays upped their price target on shares of Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the company an "overweight" rating in a report on Thursday, May 9th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $14.22.

Teva Pharmaceutical Industries Stock Up 3.2 %

Shares of TEVA stock traded up $0.52 during trading hours on Monday, reaching $16.81. The company had a trading volume of 7,976,840 shares, compared to its average volume of 11,026,337. The company has a market capitalization of $18.85 billion, a P/E ratio of -41.00, a price-to-earnings-growth ratio of 1.94 and a beta of 1.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries has a twelve month low of $7.09 and a twelve month high of $17.13. The stock's fifty day simple moving average is $14.19 and its 200 day simple moving average is $12.20.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 15,500 shares of the firm's stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the transaction, the chief accounting officer now directly owns 17,814 shares in the company, valued at approximately $299,275.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Mark Sabag sold 100,000 shares of the business's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amir Weiss sold 15,500 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $16.80, for a total value of $260,400.00. Following the completion of the sale, the chief accounting officer now directly owns 17,814 shares in the company, valued at $299,275.20. The disclosure for this sale can be found here. Insiders sold a total of 141,900 shares of company stock worth $2,013,861 over the last 90 days. Insiders own 0.55% of the company's stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several large investors have recently made changes to their positions in TEVA. New Covenant Trust Company N.A. bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $28,000. EntryPoint Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $30,000. Blue Trust Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 92.3% in the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company's stock worth $46,000 after acquiring an additional 2,180 shares during the period. Signaturefd LLC lifted its stake in shares of Teva Pharmaceutical Industries by 90.8% in the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company's stock worth $51,000 after acquiring an additional 2,394 shares during the period. Finally, Industrial Alliance Investment Management Inc. bought a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $54,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.